dGenThera develops targeted radiotherapeutics, specifically theranostic agents, for precision oncology. Their proprietary chemistry incorporates Astatine-211, Iodine-131, and Fluorine-18 with engineered stable carbon-halogen bonds. These agents, including small molecules and bioligand-tagged conjugates, are designed to target solid tumors and improve dosimetry while reducing off-target toxicity.